Thursday, July 23, 2026
← Back to archivePolicy
Policy•STAT News•Jul 23, 2026
Filing of bipartisan Senate bill boosts momentum for office of men’s health
background ▾
- •First bipartisan Senate iteration of men's health office bill in 20 years, with both House and Senate versions now active and Trump administration backing from HHS leadership
- •Bill focuses on preventive care, mental health awareness, and research coordination rather than specific drug approvals or reimbursement changes, limiting direct near-term pharma impact
- •Watch for: Congressional progress in 2025, GAO study recommendations, and potential future funding allocations that could influence men's health research priorities and market opportunities
Policy•STAT News•Jul 23, 2026
Opinion: Good riddance to bundled ‘global’ maternal care billing
background ▾
- •Starting January 1, 2027, OB-GYN billing shifts from bundled global obstetric payment to itemized fee-for-service, eliminating ambiguity around which prenatal/postpartum services should be copay-exempt under federal law
- •Current bundled system has enabled insurers to inconsistently charge copayments for preventive services that should be free, disadvantaging patients and complicating care access in rural areas where >25% of births require facility transfers
- •Monitor payer implementation of new cost-sharing structures for non-preventive services (ultrasounds, labs, delivery) and whether rural hospital participation increases under the payment reform
American College of Obstetricians and Gynecologists (ACOG)
→ Read original articlePolicy•KFF•Jul 22, 2026
Abortion Trends Before and After Dobbs
background ▾
- •Abortion volume in the U.S. has slightly increased post-Dobbs despite state-level restrictions, primarily driven by telehealth expansion and interstate access patterns rather than in-state clinic availability
Policy•Endpoints News•Jul 22, 2026
FDA swiftly puts Makary era in the rearview mirror
background ▾
- •The Trump administration is actively rolling back FDA policies established under Marty Makary's leadership
- •A new FDA commissioner is being selected, indicating potential for significant regulatory direction changes
Policy•Endpoints News•Jul 22, 2026
Former FDA cancer chief Pazdur says the agency should restructure
background ▾
- •Senior FDA oncology leadership is publicly advocating for agency restructuring, signaling internal recognition of operational challenges
Market Access
Market Access•Fierce Biotech•Jul 23, 2026
‘Substantially better than before’: Why India has golden opportunity to build on innovative R&D wins
background ▾
- •India has advanced over 10 novel drug assets in the past decade with recent regulatory and commercial validation (AbbVie $700M deal, ImmunoAct CAR-T approval, Wockhardt FDA approval), signaling a genuine shift from generics toward innovation
- •India's R&D investment gap ($2-3B annually vs. $70-75B in the U.S., $55-60B in Europe) remains a structural constraint; scaling innovation will require substantial capital influx and domestic market growth
- •Watch for: whether major Indian pharma firms (Glenmark, Zydus, Wockhardt) can sustain multiple pipeline successes, how government incentives evolve, and whether this inspires venture/institutional funding in Indian biotech
GlenmarkWockhardtZydusTecvayliNexCAR19Zaynich
→ Read original articleMarket Access•Fierce Biotech•Jul 23, 2026
Roche drops TCE for lupus, but hasn’t given up on autoimmune cell therapies
background ▾
- •Roche terminated RG6382 development for lupus due to unfavorable molecule characteristics, despite ongoing phase 1 evaluation, signaling early-stage setback in TCE autoimmune strategy.
- •Roche leadership reaffirmed strategic commitment to cell therapies for autoimmune indications via the Poseida acquisition, with additional program updates expected, indicating the company is not abandoning the space.
- •Monitor Roche's forthcoming announcements on enicepatide development and Poseida-derived cell therapy programs to assess the company's actual resource allocation and clinical progress in autoimmune cell therapeutics.
RochePoseida TherapeuticsKyverna TherapeuticsRG6382mivocabtagene autoleucelCT-868
→ Read original articleMarket Access•Endpoints News•Jul 23, 2026
Teladoc is moving beyond its single-visit roots with new launch
background ▾
- •Teladoc is shifting from a single-visit telehealth model to a broader, ongoing care platform—a significant strategic repositioning for the company's core business model
Teladoc
→ Read original articleMarket Access•Fierce Biotech•Jul 22, 2026
Royalty Pharma pens $425M deal for slice of sales on AstraZeneca’s ATTR drug
background ▾
- •Royalty Pharma's second major ATTR investment ($425M total for cliramitug) signals high commercial confidence in the asset despite AstraZeneca's recent setback with Wainua.
- •Cliramitug's novel mechanism—directly depleting misfolded transthyretin to reverse rather than delay disease—differentiates it in a crowded market but clinical validation of cardiovascular outcomes in phase 3 remains essential.
- •AstraZeneca's ATTR strategy now hinges on cliramitug's 2028 phase 3 readout; failure would undermine the franchise while approval could capture significant share in a fast-growing $7B+ market.
Royalty PharmaAstraZenecaNeurimmunecliramitugNI006Vyndaqel
→ Read original articleClinical Trials
Clinical Trials•Fierce Biotech•Jul 22, 2026
Celldex ends skin disease program after failing phase 2 test
background ▾
- •Barzolvolimab failed its primary endpoint in phase 2 PN trial despite achieving profound systemic mast cell depletion, suggesting mast cells may not be pathogenic drivers in PN and raising mechanistic doubts about the program's broader rationale
- •The phase 2 PN failure significantly weakens the case for success in the upcoming AD readout (Q4), as both conditions share pruritic disease components hypothesized to be mast-cell driven
- •Watch the Q4 atopic dermatitis phase 2 readout closely; failure could trigger broader reassessment of the barzolvolimab platform, while success would reinforce that PN failure is indication-specific rather than mechanism-of-action failure
Celldexbarzolvolimab
→ Read original articleClinical Trials•Fierce Biotech•Jul 22, 2026
Crystalys mines $130M series B to push gout drug through phase 3
background ▾
- •Dotinurad is a de-risked URAT1 inhibitor with existing approvals in Japan, China, Philippines, Taiwan and Thailand, allowing accelerated Phase 3 entry in U.S./Europe targeting the substantial second-line gout market unmet need
- •Two pivotal Phase 3 trials (Ruby comparing to allopurinol in hyperuricemia-associated gout; Topaz in tophaceous gout) are ongoing with readouts expected within the company's funded runway period
- •Watch for Phase 3 trial readouts and FDA interactions regarding clinical trial endpoints; competitive positioning versus Krystexxa (pegloticase) in the second-line space; and IPO timing if capital markets remain favorable
Crystalys TherapeuticsFrazier Life SciencesWellington Managementdotinuradallopurinolfebuxostat
→ Read original articleClinical Trials•STAT News•Jul 22, 2026
New study supports testing of Merck’s Ebola vaccine in DRC outbreak
background ▾
- •A clinical trial testing Ervebo's cross-protective efficacy against Bundibugyo virus in health workers appears imminent, potentially circumventing the months-long development timeline for Bundibugyo-specific vaccines
- •WHO remains cautious about the limited evidence for cross-species protection, but its expert committee will reconsider the proposal at its October meeting, signaling potential policy shift
- •Watch for announcement of formal trial protocol approval from DRC authorities and UNICEF's decision on release of 500,000-dose Ervebo stockpile, which will determine whether the study can proceed
MerckDoctors Without BordersAfrica CDCErveboZaire ebolavirus vaccineBundibugyo ebolavirus vaccine
→ Read original articleClinical Trials•Endpoints News•Jul 22, 2026
Arrowhead’s gene silencer competitive with Ionis’ in triglyceride disease
background ▾
- •Arrowhead's gene silencer achieved efficacy endpoints in two late-stage trials, establishing clinical competitiveness with Ionis' existing triglyceride-lowering programs
- •Success in these trials could enable label expansion into a wider patient population, materially expanding the addressable market
- •Watch for regulatory submissions and head-to-head comparative data versus Ionis therapies as both advance toward potential market entries
Arrowhead PharmaceuticalsIonis Pharmaceuticals
→ Read original articleClinical Trials•Endpoints News•Jul 22, 2026
Q&A: Lilly returns to neuropsych and looks ahead to Alzheimer's prevention
background ▾
- •Eli Lilly is re-entering/expanding its neuropsychiatry portfolio with explicit focus on Alzheimer's prevention indications
- •The announcement signals confidence in disease-modifying approaches and a shift toward earlier intervention in cognitive decline
Eli Lilly
→ Read original article